The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas. Source link.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Clinical Trials Small Molecule Pharma Companies 52

The Pharma Data

JANUARY 31, 2021

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. This press release contains forward-looking statements, including statements about the discovery, development and commercialization of products. . TOKYO and CAMBRIDGE, England , Feb. About Metrion Biosciences.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Targeted Protein Degradation Drugs Disease 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces a progress update for its R&D program focused on the design and development of novel drugs targeting the SARS-CoV-2 coronavirus and to treat COVID-19. . TOKYO and CAMBRIDGE, England , Nov. References. Hilgenfeld, Febs J.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

DECEMBER 21, 2020

A further aim of the collaboration is to generate high resolution structural information around the GPCR-E3 ligase complex to enhance drug discovery efforts as well as provide proof of concept for targeted degradation discovery approaches with other GPCRs and other target classes. No further financial details are disclosed.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40